Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C

Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C

“…However, the most relevant finding of the study is the high prognostic ability of LSM to predict clinical events and survival after transplantation: Remarkably, we have shown for the first time that LSM 1 year after transplantation is as effective as HVPG measurement (and both seem better than liver biopsy) to identify patients with different clinical outcomes in recurrent hepatitis C, in keeping with the prognostic value of LSM in immunocompetent patients (3,4). The three methods were highly accurate to identify patients who would present clinical decompensation (which is a robust clinical marker of severe recurrent hepatitis C), while LSM and HVPG measurements seemed to be more precise than liver biopsy to predict overall and HCV-related survival.…”

Hepatitis C virus infection in children and adolescents

“…Sequential testing of serum aminotransferase concentrations and regular office visits to assess for evidence of disease progression or complications is suggested. In adults with chronic hepatitis C infection, recent advancements have enabled the validation of both circulating biomarker tests and vibration‐controlled transient elastography in determining the stage of fibrosis,3, 124, 125, 126, 127, 128 progression and regression of fibrosis,129, 130, 131 as well as their use in determining liver‐related complications and overall survival 132, 133. Validation of these technologies in children and adolescents is emerging; however, the low incidence of progressive hepatitis C infection in the pediatric population will require large cohorts with extended follow‐up to determine their efficacy.…”

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

“…However, application of the algorithm in clinical practice remains to be validated. Furthermore, accumulating data provide evidence that noninvasive methods for liver fibrosis can be applied at a single point or repeatedly to provide prognostically meaningful distinctions in predicting clinical outcomes, with or without antiviral therapy, in chronic hepatitis C patients [198][199][200]. A recent study demonstrated that the 3-year evolution of the results of serial noninvasive assessment of hepatic fibrosis strongly predicts the long-term outcome in chronic hepatitis C patients [201].…”